Likopid - instructions for use, doses, side effects, contraindications

Active substanceGlucosaminylmuramyl dipeptideGlucosaminylmuramyl dipeptide

Similar drugsTo uncover

Lycopid®

pills inwards

PEPTEK, AO Russia

Dosage form: & nbsppills

Composition:

Active substance:

glucosaminylmuramyl dipeptide (GMDP) 1.0 mg.

Excipients: lactose monohydrate - 73.88 mg, sugar (sucrose) 5.0 mg, potato starch - 19.0 mg, methylcellulose - 0.12 mg, calcium stearate - 1.0 mg.

Active substance: glucosaminylmuramyl dipeptide (GMDP) - 10.0 mg.

Excipients: lactose monohydrate - 184.7 mg, sugar (sucrose) - 12.5 mg, potato starch - 40 mg, methyl cellulose - 0.3 mg, calcium stearate - 2.5 mg.

Description:Round flat cylindrical tablets of white color with a facet and a risk.

Pharmacotherapeutic group:Immunomodulating agent

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

The active substance of the tablets Likopid® - glucosaminylmuramidipeptide (GMDP) - is a synthetic analog of the structural fragment of the membrane (peptidoglycan) of bacterial cells. GMDP is an activator of innate and acquired immunity, strengthens the body's defense against viral, bacterial and fungal infections; has an adjuvant effect in the development of immunological reactions.

Biological activity of the drug is realized by binding of GMDP to intracellular receptor protein NOD2, localized in the cytoplasm of phagocytes (neutrophils, macrophages, dendritic cells).The drug stimulates the functional (bactericidal, cytotoxic) activity of phagocytes, enhances their presentation of antigens, proliferation of T and B lymphocytes, increases the synthesis of specific antibodies, helps normalize the balance Th1 / Th2-lymphocytes in the direction of predominance of Th1. Pharmacological action is carried out by increasing the production of key interleukins (interleukin-1, interleukin-6, interleukin-12), tumor necrosis factor alpha, gamma-interferon, colony-stimulating factors. The drug increases the activity of natural killer cells.

Likopid® has low toxicity (LD50 exceeds the therapeutic dose of 106,000 times or more). In the experiment with the oral method of administration in doses 100 times higher than the therapeutic, the drug does not have a toxic effect on the central nervous and cardiovascular systems, does not cause pathological changes on the part of internal organs. Likopid® does not have embryotoxic and teratogenic effects, does not cause chromosomal, gene mutations. In experimental studies conducted on animals, data were obtained on the antitumor activity of Lycopida® (GMDP).

Pharmacokinetics:

Bioavailability of the drug for oral administration is 7-13%. The degree of binding to blood albumins is weak. The time to reach the maximum concentration (tmax) -1,5 hours after admission. Half-life (t1/2) - 4.29 hours. There are no active metabolites, it is excreted mainly through the kidneys in unchanged form.

Indications:

The drug is used in adults and children (from 3 years) in the complex treatment of diseases accompanied by secondary immunodeficiency states:

Children:

- chronic, recurrent infections of the upper and lower respiratory tract in the stage of exacerbation and remission;

- Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others);

herpes infection.

Adults:

- chronic respiratory tract infections;

- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others;

herpes infection.

Prophylactic reception (adults):

- prevention and reduction of seasonal morbidity ARI and frequency of exacerbations of chronic diseases of ENT organs, upper and lower respiratory tract.

Contraindications:

Hypersensitivity to glucosaminylmuramyl dipeptide and other components of the drug;

pregnancy and lactation;

autoimmune thyroiditis in the phase of exacerbation;

conditions accompanied by febrile temperature (> 38 ° C) at the time of taking the drug;

rare congenital metabolic disorders: alaktasia, galactosemia, lactase deficiency, lactose intolerance, sugarase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;

application in autoimmune diseases is not recommended due to the lack of clinical data.

Carefully:

Each Lycopid® 1 mg tablet contains sucrose in an amount of 0.00042 h.p. (bread units), which should be taken into account in patients with diabetes mellitus.

Each Lycopid® 1 mg tablet contains 0.074 grams of lactose, which should be taken into account for patients suffering from hypolactasia (lactose intolerance, in which the level of lactase, the enzyme necessary for digesting lactose, is reduced in the body).

Each Likopid® 10 mg tablet contains sucrose in an amount of 0.001 h.p. (bread units), which should be taken into account in patients with diabetes mellitus.

Each tablet contains 10 mg Likopid® 0.184 grams lactose, which should be considered for patients suffering hypolactasia (lactose intolerance, in which the body is observed decline of lactase - enzyme necessary for digesting lactose).

Pregnancy and lactation:

Taking Likopid® 1 mg is contraindicated in women during pregnancy and breastfeeding.

Dosing and Administration:

Likopid® is administered orally or sublingually on an empty stomach, 30 minutes before meals.

If you skip the drug, if you have not more than 12 hours from the scheduled time, you can take the missed dose; in the event that more than 12 hours have elapsed from the scheduled time of admission, it is necessary to take only the next dose and not to take the missed dose.

Dose adjustments in individual patient groups (elderly persons, patients with impaired liver function, patients with impaired renal function) are not required.

Children:

Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 1 tablet once a day under the tongue for 10 days.

Chronic, recurrent infections of the upper and lower respiratory tract (in the stage of exacerbation and remission): Lycopid® take 3 courses of 1 tablet 1 time per day under the tongue for 10 days, with a break between courses in 20 days. Herpetic infection: 1 tablet 3 times a day inside or under the tongue for 10 days.

Adults:

Chronic respiratory tract infections: 2 tablets once a day under the tongue for 10 days.

Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 2 tablets 2-3 times a day under the tongue for 10 days.

Herpetic infection: 2 tablets 3 times a day inside or under the tongue for 10 days.

Prevention (adults):

for the prevention or reduction of seasonal morbidity of acute respiratory disease and the frequency of exacerbations of ENT diseases, upper and lower respiratory tract Likopid® take 1 tablet 3 times a day under the tongue for 10 days.

Side effects:

Often (1-10%) - Arthralgia (joint pain), myalgia (pain in the muscles); at the beginning of treatment there may be a short-term increase in body temperature to subfebrile values (up to 37.9 ° C), which is not an indication for the withdrawal of the drug.Most often, the above-described side effects are observed when taking Likopid® tablets in high doses (20 mg).

Rarely (0.01-0.1%) - a short-term increase in body temperature to febrile values (> 38.0 ° C). With an increase in body temperature of more than 38.0 ° C, antipyretic agents may be taken, which does not reduce the pharmacological effects of Likopid® tablets.

Very rarely (less than 0.01%) - diarrhea.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, report about this to the attending physician.

Overdose:

Cases of drug overdose are unknown.

Based on the pharmacological properties of the drug, in case of overdose it can be observed a rise in body temperature to subfebrile (up to 37.9 ° C) values. If necessary, symptomatic therapy (antipyretics) is carried out, sorbents are appointed. The specific antidote is unknown.

Interaction:

The drug increases the effectiveness of antimicrobial drugs, there is synergy with antiviral and antifungal agents. Antacids and sorbents significantly reduce the bioavailability of the drug.Glucocorticosteroids reduce the biological effect of Lycopida®.

Special instructions:

At the beginning of taking Likopida® 10 mg, the symptoms of chronic and latent-related diseases may worsen due to the basic pharmacological effects of the drug.

In the elderly, Likopid® 10 mg is administered with caution, strictly under the supervision of a physician. Elderly patients are advised to start treatment with half the dose (1/2 of the therapeutic dose), in the absence of side effects, increasing the dose of the drug to the required therapeutic dose.

The decision to prescribe the drug Likopid® tablets 10 mg for patients with a combination of diagnoses of "psoriasis" and "gout" should be taken by the doctor when assessing the risk / benefit ratio, due to the potential risk of exacerbation of gouty arthritis and joint swelling. If the doctor decides to prescribe Likopid® 10 mg tablets in a situation where the patient is diagnosed as having "psoriasis" and "gout," treatment should begin with low doses, in the absence of side effects, increasing the dose to the therapeutic dose.

Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive a car and complex machinery.

Form release / dosage:

Tablets of 1 mg, 10 mg.

Packaging:

For 10 tablets in a contour mesh box made of polyvinyl chloride film and aluminum foil printed lacquered. On 1 contour cellular packing together with the instruction on medical application place in a pack from a cardboard.

Storage conditions:

In dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LS-001438

Date of registration:23.09.2011 / 23.09.2016

Expiration Date:Unlimited

The owner of the registration certificate:PEPTEK, AO PEPTEK, AO Russia

Manufacturer: & nbsp

PEPTEK, AO Russia

ZIO-HEALTH, JSC Russia

Information update date: & nbsp17.06.2017

Illustrated instructions

Instructions

Lycopid® (Licopid®)